Skip to content
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • about
    • executive management
    • scientific advisory board
    • board of directors
  • our science
    • organ fibrosis
    • HGF/c-met pathway
  • pipeline
    • ANG-3070
    • ANG-3777
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • stock information
      • stock quote & chart
      • historic price lookup
    • analyst coverage
    • press releases
    • events & presentations
    • sec filings
    • governance
    • investor resources
      • investor contact
      • investor FAQs
      • email alerts
  • publications
  • careers
  • contact

Author: David Miller

October 22, 2020February 5, 2021

Compartmental Differences Within the COL3A1 Network in Proteinuric Kidney Disease — Informing Drug Activity Using the Jaccard-Tanimoto Index

Posted in angion publications
October 22, 2020February 5, 2021

Design of the Graft Improvement Following Transplant (GIFT) Trial, a Phase 3 Study of ANG-3777 in Kidney Transplantation Patients with Delayed Graft Function

Posted in angion publications
October 22, 2020February 5, 2021

The Effect of ANG-3777 on In Vitro Cell Proliferation

Posted in angion publications
July 29, 2020February 5, 2021

Financial Impact of Delayed Graft Function in Kidney Transplantation

Posted in angion publications
July 3, 2020February 5, 2021

The Rho Kinases: Critical Mediators of Multiple Profibrotic Processes and Rational Targets for New Therapies for Pulmonary Fibrosis (Knipe, et al)

Posted in ROCKi
July 3, 2020February 5, 2021

Role of receptor tyrosine kinase signaling in renal fibrosis (Liu & Zhuang)

Posted in Fibrosis
July 1, 2020February 5, 2021

Drug and targets in fibrosis (Li, et al)

Posted in Fibrosis
July 1, 2020February 5, 2021

Acute Lung Injury: Epidemiology, Pathogenesis, and Treatment (Johnson & Mathay)

Posted in RSL-ALI
July 1, 2020February 5, 2021

Acute respiratory distress syndrome: epidemiology and management approaches (Walkey, et al)

Posted in RSL-ALI
July 1, 2020February 5, 2021

Cost and Healthcare Utilization in ARDS – Different from Other Critical Illness? (Bice, et al)

Posted in RSL-ALI

Posts navigation

Older posts
Newer posts

CATEGORIES

  • RSL-HGF
  • RSL-ALI
  • Fibrosis
  • ROCKi
  • angion publications
  • RSL-AKI
  • events

CORPORATE ADDRESS

7 Wells Avenue
Suite 14
Newton, MA 02459

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© 2023 Angion. All Rights Reserved.
Legal and Privacy Policy

BOSTON | AUSTRALIA